Condition: Cervical Cancer · HPV-Related Carcinoma · HPV-Related Malignancy · Sponsor: Precigen, Inc
This Phase 2 study will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
This description comes directly from the study's public registry record.
Amy Lankford · 3015569900 · clinicaltrials@precigen.com
Always discuss trial participation with your own doctor first.
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | Recruiting |
| National Institute of Health | Bethesda, Maryland, United States | Recruiting |
| University of Washington | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06157151